Swedish Orphan Biovitrum AB 

Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. Its primary therapeutic focus areas encompass hematology, immunology, and a range of genetic and metabolic disorders, with a commercial presence across Europe, North America, and other international markets. The company's diverse portfolio includes medications addressing critical conditions such as hemophilia B (Alprolix) and hemophilia A (Elocta), thrombocytopenia (Doptelet), hemophagocytic lymphohistiocytosis (Gamifant), and hereditary tyrosinemia type-1 (Orfadin). Additionally, it provides Kineret for multiple inflammatory diseases, including cryopyrin-associated periodic syndrome, rheumatoid arthritis, and Still's disease, alongside Synagis for severe lower respiratory tract infections. Sobi's broader product range further comprises various other therapeutics like Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. Beyond its proprietary offerings, Sobi is involved in the development of drug substances for external partners, notably ReFacto AF/Xyntha for Pfizer, as well as advancing BIVV001 for hemophilia A and Nirsevimab, which targets respiratory syncytial virus. A key strategic collaboration exists with Apellis Pharmaceuticals Inc. for the co-development of pegcetacoplan, aimed at treating a spectrum of rare diseases, such as paroxysmal nocturnal hemoglobinuria. The company maintains its headquarters in Solna, Sweden.